The multi-center morphometric mammary carcinoma project (MMMCP) in the netherlands: Value of morphometrically assessed proliferation and differentiation
✍ Scribed by Jan P. A. Baak; Paul J. Van Diest; Tineke Benraadt; Erna Matze-Cok; Jane Brugghe; Leonard T. Schuurmans; J. J. Littooy
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 450 KB
- Volume
- 53
- Category
- Article
- ISSN
- 0730-2312
No coin nor oath required. For personal study only.
✦ Synopsis
The Multi-Center Morphometric Mammary Carcinoma Project (MMMCP) was set up to investigate the reproducibility and prognostic value of routine assessments of morphometric parameters [mean nuclear area (MNA), mitotic activity index (MAI), and multivariate prognostic index (MPI)] and cytometric features (DNA ploidy and index, % S-phase cells, as well as other cell cycle data) in comparison with classical prognostic parameters and steroid receptors. Thirty-four hospitals in six geographic regions participated. In 1988participated. In -1989, 3427 , 3427 patients entered the study and morphometric assessments were made. An interim (1993) survival analysis indicated that MAI, MNA, and MPI are the strongest predictors of outcome. A Phase I11 randomized prospective multi-center trial [Premenopausal Morphometric Intervention Study (PREMIS)] using these endpoints was initiated in Europe to evaluate adjuvant [cyclophosphamide, methotrexate and 5-fluorouracil (CMF)] chemotherapy versus observation in morphometrically high risk (i.e., MA1 > lo), premenopausal, lymph node negative (LN-) breast cancer patients.